Posted by Michael Wonder on 10 Jan 2017
Fiasp (fast-acting insulin aspart) approved in Europe
10 January 2017 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Fiasp for the treatment of diabetes in adults. The authorisation covers all 28 European Union member states.
Fiasp is the brand name for fast-acting insulin aspart. Fiasp provides improved mealtime and overall glucose control with a similar safety profile versus NovoRapid.
"Fiasp is a new-generation mealtime insulin; it is an innovative faster formulation of insulin aspart that more closely mimics the physiological insulin response around meals. The incremental benefits with Fiasp are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.
Fiasp will be available in vial, Penfill and FlexTouch pen.
